World’s first clinical trial for a rare headache disorder
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Complementary business models are the reason for the acquisition
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
Subscribe To Our Newsletter & Stay Updated